BC
OCUL icon

Bridgefront Capital’s Ocular Therapeutix OCUL Stock Holding History

Bridgefront Capital’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$303K Sell
30,853
-12,498
-29% -$113K 0.08% 380
2026
Q1 		$367K Buy
+43,351
New +$413K 0.09% 338
2021
Q3 		– Sell
-17,141
Closed -$243K – 582
2021
Q2 		$243K Buy
+17,141
New +$261K 0.09% 429

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bridgefront Capital's OCUL Position: Q2 2026 in Review

Bridgefront Capital reduced its Ocular Therapeutix (OCUL) stake by 29% in Q2 2026, selling an estimated $113K and leaving 30,853 shares worth $303K. The position accounts for 0.08% of the portfolio, ranked #380.

Bridgefront Capital first reported a position in OCUL in Q2 2021 and has held it in 3 quarters since. The position peaked at $367K in Q1 2026. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Bridgefront Capital held 30,853 shares of Ocular Therapeutix worth $303K as of Q2 2026.
  • Bridgefront Capital sold 12,498 Ocular Therapeutix shares in Q2 2026, an estimated $113K.
  • Ocular Therapeutix made up 0.08% of Bridgefront Capital's portfolio in Q2 2026, its #380 holding.
  • Bridgefront Capital first reported a position in Ocular Therapeutix in Q2 2021 and has held it in 3 quarters since.
  • Bridgefront Capital's Ocular Therapeutix position peaked at $367K in Q1 2026.
  • 262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.